

# CITATION REPORT

List of articles citing

**Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study**

**DOI: 10.1200/jco.18.01580**

**Journal of Clinical Oncology, 2019, 37, 269-277.**

**Source:** <https://exaly.com/paper-pdf/73649261/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
220	Venetoclax/Rituximab bei CLL. <b>2019</b> , 22, 44-44		
219	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <b>2019</b> , 381, 788-789		11
218	Venetoclax/Rituximab bei CLL: 2-jährige Therapie auch nach Absetzen vorteilhaft. <b>2019</b> , 22, 13-14		
217	Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies. <b>2019</b> , 79, 1287-1304		13
216	How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options. <b>2019</b> , 21, 74		4
215	Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials. <b>2019</b> , 10, 697		15
214	A one-two punch with VO KOs CLL. <b>2019</b> , 133, 2737-2738		
213	Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. <b>2019</b> , 94, 1266-1287		198
212	Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?. <b>2019</b> , 9, 689		18
211	Chronic lymphocytic leukemia paradigm continues to be refined: news from the American Society of Hematology 2018 annual meeting. <b>2019</b> , 8, IJH14		
210	Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia. <b>2019</b> , 14, 493-504		4
209	Aktuelle Therapiestrategien zur chronischen lymphatischen Leukämie. <b>2019</b> , 25, 1004-1008		
208	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. <b>2019</b> , 9, 443		20
207	Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL). <b>2019</b> , 10, 2484-2485		2
206	SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. <b>2019</b> , 19, 321-325		1
205	How to approach CLL in clinical practice. <b>2019</b> , 37 Suppl 1, 38-42		10
204	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 T cells and impede CAR T-cell efficacy. <b>2019</b> , 134, 44-58		69

203	Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era. <b>2019</b> , 39, 487-498	6
202	Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia. <b>2019</b> , 104, e434-e437	81
201	Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. <b>2019</b> , 19, 423-430	16
200	Is venetoclax a new wonder drug in CLL?. <b>2019</b> , 185, 643-646	
199	Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?. <b>2019</b> , 11, e2019024	3
198	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <b>2019</b> , 133, 1964-1976	72
197	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <b>2019</b> , 133, 2765-2775	42
196	Venetoclax in the treatment of chronic lymphocytic leukemia. <b>2019</b> , 15, 353-366	18
195	Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. <b>2019</b> , 104, 2144-2154	19
194	Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?. <b>2019</b> , 3,	
193	Targeted Therapy in Chronic Lymphocytic Leukemia. <b>2019</b> , 25, 378-385	14
192	Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies. <b>2019</b> , 9, 1421	16
191	Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. <b>2019</b> , 25, 418-427	6
190	Emerging treatment options for patients with p53-pathway-deficient CLL. <b>2019</b> , 10, 2040620719891356	12
189	From Biology to Therapy: The CLL Success Story. <b>2019</b> , 3, e175	29
188	The evolving treatment landscape of chronic lymphocytic leukemia. <b>2019</b> , 31, 568-573	7
187	BCL-2 Inhibitors, Present and Future. <b>2019</b> , 25, 401-409	10
186	Relevance of Minimal Residual Disease in the Era of Targeted Agents. <b>2019</b> , 25, 410-417	4

185	Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia. <b>2019</b> , 25, 428-435	8
184	Targeted Therapies in Chronic Lymphocytic Leukemia: Is 2 (or 3) Better Than 1?. <b>2019</b> , 25, 449-454	0
183	Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?. <b>2019</b> , 3, e287	19
182	MRD to help assess response in CLL. <b>2019</b> , 16, 68	
181	Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics. <b>2020</b> , 39, 1167-1184	32
180	Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. <b>2020</b> , 34, 924-928	1
179	Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. <b>2020</b> , 188, 844-851	11
178	Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. <b>2020</b> , 38, 129-136	10
177	An update on: molecular genetics of high-risk chronic lymphocytic leukemia. <b>2020</b> , 13, 109-116	3
176	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies. <b>2020</b> , 10, 591577	18
175	Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO). <b>2020</b> , 4, e473	9
174	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4042-4054	2.2 66
173	Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. <b>2020</b> , 13, 871-883	5
172	BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic. <b>2020</b> , 12,	5
171	Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. <b>2021</b> , 144, 365-379	5
170	Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance. <b>2020</b> , 12,	5
169	Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. <b>2020</b> , 2020, 33-40	4
168	Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. <b>2020</b> , 2020, 357-362	6

167	Therapeutic development and current uses of BCL-2 inhibition. <b>2020</b> , 2020, 1-9	17
166	Approaches for relapsed CLL after chemotherapy-free frontline regimens. <b>2020</b> , 2020, 10-17	5
165	The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia. <b>2020</b> , 13, 885-894	0
164	Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. <b>2020</b> , 19, 1105-1120	2
163	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3626-3637 <sup>2,2</sup>	34
162	Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics. <b>2020</b> , 8, 329-342	2
161	An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. <b>2020</b> , 13, 1039-1046	1
160	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. <b>2020</b> , 21, 1188-1200	92
159	Venetoclax plus obinutuzumab therapy for front-line treatment of chronic lymphocytic leukaemia. <b>2020</b> , 21, 1128-1130	1
158	Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib. <b>2020</b> , 61, 3422-3431	0
157	Leukämien. <b>2020</b> , 35, 352-354	
156	14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL. <b>2021</b> , 100, 509-518	6
155	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. <b>2020</b> , 4, e432	15
154	Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia. <b>2020</b> , 9, IJH31	2
153	Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance $\geq 30$ mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations. <b>2020</b> , 10, e039168	4
152	UGT2B17 modifies drug response in chronic lymphocytic leukaemia. <b>2020</b> , 123, 240-251	5
151	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. <b>2020</b> , 135, 2402-2412	43
150	Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives. <b>2020</b> , 12,	5

149	Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm. <b>2020</b> , 15, 168-176	2
148	The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia. <b>2020</b> , 15, 343-349	1
147	Cell Death in the Origin and Treatment of Cancer. <b>2020</b> , 78, 1045-1054	46
146	Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape. <b>2020</b> , 21, 24	22
145	Precision Medicine Management of Chronic Lymphocytic Leukemia. <b>2020</b> , 12,	16
144	Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer. <b>2020</b> , 12,	24
143	Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. <b>2020</b> , 136, 2918-2926	21
142	Response in patients with -mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab. <b>2020</b> , 105, e382-e383	3
141	The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?. <b>2020</b> , 13, 771-779	2
140	Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm. <b>2020</b> , 22, 16	14
139	Is There a Role for Chemotherapy in the Era of Targeted Therapies?. <b>2020</b> , 15, 72-82	2
138	The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia. <b>2020</b> , 20, 799-812	3
137	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. <b>2020</b> , 105, 2440-2447	14
136	Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia. <b>2020</b> , 189, e49-e52	3
135	Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib. <b>2020</b> , 25, 25-35	10
134	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). <b>2020</b> , 105, 2671-2674	
133	Diagnose und Behandlung der chronischen lymphatischen Leukämie. <b>2020</b> , 15, 8-16	
132	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?. <b>2020</b> , 111, 642-656	1

131	CAR-T treatment for hematological malignancies. <b>2020</b> , 68, 956-964	9
130	A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. <b>2020</b> , 190, 736-740	4
129	How I manage CLL with venetoclax-based treatments. <b>2020</b> , 135, 1421-1427	9
128	How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. <b>2020</b> , 42, 103-110	26
127	Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review. <b>2020</b> , 20, e414-e426	5
126	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. <b>2020</b> , 4, 165-173	17
125	Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia. <b>2021</b> , 109, 424-432	3
124	Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia. <b>2021</b> , 137, 1117-1120	13
123	Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2021</b> , 32, 23-33	92
122	Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia. <b>2021</b> , 62, 791-800	0
121	Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. <b>2021</b> , 62, 1129-1135	5
120	A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. <b>2021</b> , 137, 600-609	28
119	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. <b>2021</b> , 35, 1597-1609	3
118	Anti-CD20 treatment for B-cell malignancies: current status and future directions. <b>2021</b> , 21, 161-181	6
117	Der Stand der Therapie bei der refraktären/rezidivierenden chronischen lymphatischen Leukämie: Neuartige Wirkstoffe im Fokus. <b>2021</b> , 8, 59-69	
116	Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020. <b>2021</b> , 12, 20-22	2
115	Immunophenotypic Profile of Blast Cells as a Marker for Diagnosis of Relapsed Children Acute Lymphoblastic Leukemia. <b>2021</b> , 6, 56-64	
114	Sex as decisive variable in lymphoid neoplasms-an update. <b>2021</b> , 6, 100001	1

113	Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far. <b>2021</b> , 22, 655-665	3
112	Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. <b>2021</b> , 193, 325-338	3
111	Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance. <b>2021</b> , 13,	9
110	From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. <b>2021</b> , 13,	1
109	How I treat chronic lymphocytic leukemia after venetoclax. <b>2021</b> , 138, 361-369	1
108	Current Treatment Options in CLL. <b>2021</b> , 13,	4
107	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. <b>2021</b> , 11,	2
106	Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective. <b>2021</b> , 2, 628-634	0
105	Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia. <b>2021</b> , 1, 249-262	
104	Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy. <b>2021</b> , 16, 325-335	0
103	To start and stop or just keep going?. <b>2021</b> , 138, 819-820	
102	Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax. <b>2021</b> , 37, 1409-1420	3
101	Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. <b>2021</b> , 138, 1805-1816	1
100	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. <b>2021</b> , 138, 836-846	6
99	Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?. <b>2021</b> , 13,	1
98	Time-limited, Combined Regimen in Chronic Lymphocytic Leukemia: A Promising Strategy to Achieve a Drug Holiday. <b>2021</b> , 41, 431-442	0
97	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <b>2021</b> , 35, 3059-3072	6
96	Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression. <b>2021</b> , 11, 127	2



95	Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis. <b>2021</b> , 1	1
94	BCL2 and MCL1 inhibitors for hematologic malignancies. <b>2021</b> , 138, 1120-1136	7
93	The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications. <b>2021</b> , 27, 266-274	0
92	The future of antibody therapy in chronic lymphocytic leukemia. <b>2021</b> , 26, 323-336	0
91	Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib. <b>2021</b> ,	1
90	Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?. <b>2021</b> , 35, 775-791	3
89	The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. <b>2021</b> , 33, 670-680	0
88	Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?. <b>2021</b> , 35, 3364-3370	0
87	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. <b>2021</b> , 13,	9
86	A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents. <b>2021</b> , 39, 595-604	3
85	Relapsed Chronic Lymphocytic Leukaemia with Concomitant Extensive Chronic Graft versus Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation Successfully Treated with Oral Venetoclax. <b>2021</b> , 2021, 8831125	1
84	Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia. <b>2019</b> , 1143, 95-128	1
83	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. <b>2020</b> , 135, 2266-2270	35
82	Relapsed disease and aspects of undetectable MRD and treatment discontinuation. <b>2019</b> , 2019, 482-489	1
81	Treatment of relapsed chronic lymphocytic leukemia after venetoclax. <b>2020</b> , 2020, 18-23	3
80	Targeted therapy in CLL: changing the treatment paradigm. <b>2019</b> , 10, 4002-4003	1
79	Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.. <b>2020</b> , 3, 415-444	2
78	Measurable residual disease in the treatment of chronic lymphocytic leukemia. <b>2020</b> , 60, 138-145	0

- 77 The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. **2021**, 16
- 76 Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. **2021**, 96, 1679-1705 19
- 75 Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. *Journal of Clinical Oncology*, **2021**, 39, 3853-3865 2.2 17
- 74 Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma. **2019**, 1-22
- 73 Chronic Lymphocytic Leukemia. **2019**,
- 72 Wenetoklaks w leczeniu chorób układu krwiotwórczego i guzów litych. **2019**, 50, 41-50
- 71 Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia.. **2020**, 3, 532-549
- 70 Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. *Journal of Clinical Oncology*, **2021**, JCO21011781 10
- 69 Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. **2021**, 0
- 68 High-Throughput immunogenetics for precision medicine in cancer. **2021**, 0
- 67 Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. **2021**, 27, 1532-1544 1
- 66 Updates in the Management of CLL/SLL: Sequencing Therapy and the Role of Minimal Residual Disease Testing. **2020**, 18, 1756-1759 3
- 65 Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma. **2020**, 1087-1108
- 64 ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. **2020**, B-1-B30-3
- 63 [Resistance mechanisms and treatment strategies of Venetoclax in chronic lymphocytic leukemia]. **2020**, 41, 783-787
- 62 Minimal Residual Disease Assessment in CLL/SLL: Is It Ready for Routine Clinical Practice?. **2021**, 19, 1343-1345
- 61 Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center.
- 60 Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. **2021**, 229, 114009 7

59	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. <b>2021</b> , 8, e879-e890	13
58	Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1.. <b>2021</b> , 11, 777587	0
57	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). <b>2021</b> , 106, 2834-2844	1
56	Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.. <b>2021</b> , 11, 780085	1
55	CLL update 2022: A continuing evolution in care.. <b>2022</b> , 100930	1
54	Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.. <b>2022</b> , 17, 39	
53	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.. <b>2022</b> ,	10
52	Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.. <b>2022</b> , 1-8	
51	Real-world management of targeted therapies in chronic lymphocytic leukemia.. <b>2022</b> , 10781552221090869	1
50	Guideline for the treatment of chronic lymphocytic leukaemia.. <b>2022</b> ,	0
49	Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GiVe) in patients with untreated high-risk chronic lymphocytic leukemia.. <b>2021</b> ,	6
48	Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.. <b>2022</b> , 9, e190-e199	4
47	A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies.	
46	The Difficult-to-Treat del 17 p Patient-A Case Report in Chronic Lymphocytic Leukemia.. <b>2021</b> , 58,	0
45	BTKi, venetoclax, obinutuzumab: what is the ideal combination?. <b>2022</b> , 15, 49-52	0
44	Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia. <b>2021</b> , 23, 612-620	1
43	The therapy for early relapsed chronic lymphocytic leukemia: the development of the problem&#x0D; The results of the project with the discussion concerning the possibility of optimization approaches for the therapy. <b>2021</b> , 23, 610-611	
42	High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.. <b>2022</b> ,	0

41	DataSheet_1.pdf. <b>2020</b> ,	
40	Image_1.jpeg. <b>2019</b> ,	
39	Image_2.jpeg. <b>2019</b> ,	
38	Table_1.docx. <b>2019</b> ,	
37	Defining disease modification in myelofibrosis in the era of targeted therapy.. <b>2022</b> ,	2
36	CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche.. <b>2022</b> , 23,	0
35	Ibrutinib Plus Venetoclax for First-Line Chronic Lymphocytic Leukemia Treatment.	
34	Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells.. <b>2022</b> ,	
33	Circulating tumor DNA-based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib and venetoclax.. <b>2022</b> ,	0
32	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.	4
31	Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination. <b>2022</b> , 15,	0
30	Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib.	
29	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.	1
28	NCCN Guidelines <sup>®</sup> Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. <b>2022</b> , 20, 622-634	4
27	Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?.	0
26	Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. 1-14	0
25	Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukaemia and Potential Future Therapeutic Directions. <b>2022</b> ,	
24	Patient preferences regarding treatment options for Waldenström's macroglobulinemia: A discrete choice experiment.	0

23	Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. 1-20	
22	Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. <b>2022</b> ,	1
21	Approved and emerging Bruton tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. 1-13	
20	Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. <b>2022</b> , 18, 2943-2966	1
19	Minimal/Measurable Disease Analysis in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma by Flow Cytometry. <b>2022</b> , 2,	
18	Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies. 12,	1
17	Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?.	0
16	MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. 00-00	0
15	Small molecule inhibitors targeting the cancers. <b>2022</b> , 3,	0
14	Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.	1
13	Modern Approach to Prognostication and Therapy of Chronic Lymphocytic Leukemia. <b>2022</b> ,	0
12	Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. 1-15	1
11	A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.	0
10	Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. 1-5	1
9	Receptor-Mediated Redox Imbalance: An Emerging Clinical Avenue against Aggressive Cancers. <b>2022</b> , 12, 1880	0
8	Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. 1-12	0
7	Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience.	0
6	Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report. <b>2023</b> , 21, 102-107	0

- 5 The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials. 13, ○
- 4 Emerging Therapies in CLL in the Era of Precision Medicine. **2023**, 15, 1583 ○
- 3 Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia. ○
- 2 Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. **2023**, ○
- 1 Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. **2023**, 14, ○